INTRODUCTION
Lineage commitment and differentiation along the hemo-lymphoid pathway rely heavily on Ikaros, which encodes a number of Krüppel-type zinc finger proteins (1) (2) (3) (4) . Ikaros contains seven coding exons, four of which can be alternatively utilized to generate a number of isoforms (5, 6) . These Ikaros proteins differ in the number of N-terminal zinc fingers which constitute their DNA binding domain. Ikaros isoforms with at least three N-terminal zinc fingers (i.e. Ik-1, Ik-2 and Ik-3) are capable of binding a high affinity Ikaros site that contains the GGGAA core motif whereas all other isoforms cannot bind this site (5) . Nonetheless, all of the Ikaros isoforms share two hunchback-related zinc fingers at their C-terminus, which are necessary for dimerization between Ikaros proteins and family members (7). Interactions between Ikaros isoforms that can and cannot bind DNA compromise the ability of the resulting complex to bind DNA (7, 8) . This indicates that the non-DNA binding Ikaros isoforms can act as naturally occurring dominant negative factors to regulate the activity of the DNA binding isoforms.
A role for Ikaros is manifested from the earliest steps of the hemopoietic pathway. differentiation towards the CD4/TCRαβ lineage (10) . The limited number of Ikaros deficient thymocytes and mature T cells display a TCR-mediated hyperproliferative phenotype in vitro and undergo rapid clonal expansions in vivo (10) . Mice homozygous for a mutation that generates only dominant negative Ikaros isoforms display similar but more severe defects (8). In addition to the B and NK cell deficiency, they lack all fetal and adult T cells. Mice heterozygous for this mutation have lymphocyte populations that appear normal; however, their T cells display augmented TCR-mediated proliferative responses and they rapidly develop leukemias and lymphomas (11) (12) (13) . The more severe phenotype of the dominant negative compared to the null mice suggested the presence of family members whose activity was affected by this mutation. Consistent with this hypothesis, three family members were identified -Aiolos (14) , Helios (15, 16) and Eos/Daedalus (17, 18) -that are more restricted in hemopoietic expression relative to Ikaros.
The aforementioned studies identify Ikaros as an important regulator of several steps in the hemo-lymphoid pathways (2, 3, 4, 19) . The mechanisms by which Ikaros operates along this pathway have been the focus of diverse studies, some of which implicate it as a repressor of gene expression for the following reasons. First, in actively cycling primary lymphocytes, Ikaros concentrates in distinctive toroidal structures, which are found in apposition to pericentromeric heterochromatin and a variety of transcriptionally silent genes (20) . Second, in late S phase, some of the Ikaros toroids become coincident with clusters of DNA replication origins, which presumably are sites of replicating heterochromatin (12) . Third, a biochemical purification of Ikaros from lymphocytes has determined that the majority of Ikaros exists within a stable 2MD complex containing components of the NuRD complex which include the ATPase, Mi-2β, and Class I histone deacetylases which are presumed to play a role in repression (21) , while a smaller fraction of Ikaros also interacts with the putative co-repressors Sin3 and CtBP (22, 23) . Fourth, heterologous fusions of Ikaros to the Gal4 DNA binding domain behave as potent transcriptional repressors (22) . Furthermore, recent studies have suggested that Ikaros may be involved in the repression of the λ5 and TDT genes (24, 25) .
Ikaros has also been reported to function as an activator of transcription. Ectopic expression of Ikaros with reporters containing engineered Ikaros sites in non-lymphoid cells results in gene activation (1, 5, 7) . Gene expression profiling experiments in Ikarosdeficient hemopoietic precursors further support such a role: expression of the tyrosine kinase receptors flk-2 and c-kit in early hemopoietic progenitors is reduced in the absence of Ikaros (9). Ikaros has also been reported to activate from the enhancer of an MCF virus (26) . Additionally, Ikaros functions as a suppressor of variegation for regulatory elements of the CD8 locus (D. Kioussis, personal communication).
Ikaros' potential to function as a repressor and activator of gene expression may provide a molecular basis for its diverse effects in the hemo-lymphoid system. To gain further insight into this important problem in lymphocyte biology, we have undertaken a comprehensive analysis of the transcriptional properties of Ikaros. Here we report that Ikaros is indeed capable of enhancing gene expression as a potentiator of bona fide transcriptional activators and not by functioning as a classical activator. Potentiation by Ikaros requires its intact DNA binding and dimerization domains, both of which are necessary for its recruitment into a PC-HC associated nuclear compartment in cycling cells. We show that there is an unexpected correlation between Ikaros localization to these heterochromatin-associated sites and its ability to activate gene expression. These studies also indicate that the presence of Ikaros in this nuclear compartment provide a "landing pad" for its chromatin remodeling partner Mi-2β and presumably the NURD complex. Two models are proposed to explain these findings.
EXPERIMENTAL PROCEDURES
Plasmids -4X IkBS2tkCAT and tkCAT have been previously described (5).
4XIKAS1tkCAT were constructed by cloning ligated oligos containing the corresponding sites into the tkCAT reporter by standard cloning methods.
4XSp1E1BCAT, G5E1BCAT, CMV2Flag, CMV2Flag-Ik1, CMV2Flag-Ik1M, BXG1 and BXG1-Ik1 have been described previously (22, 23) . CMV2Flag-Ikaros and BXG1-Ikaros DBD and activation domain mutants described in this paper were constructed using the Stratagene Mutagenesis kit.
Transfections -293T and NIH-3T3 cell lines were maintained in Dulbecco's modified
Eagle's medium with 10% fetal bovine serum (Hyclone). Transfections of these cell lines were carried out using the HBS-CaP0 4 method. For repression assays, 1µg of the Gal4-fusion plasmid, 10µg of the Gal4-reporter plasmid and 0.5µg of the pXGH5 growth hormone control plasmid were used. For activation assays, typically 1.5µg of the reporter, 0.25µg of Ikaros expression plasmid and 0.5µg of the GH plasmid were used.
Twenty-four hours after transfection, cells were fed with fresh media and 18-24 hours later cells were harvested and processed for CAT assays as described (22) . Growth hormone assays were done as recommended by the manufacturer (Nichols Institute).
Transfections were typically performed in duplicate and repeated between three to six times. For interaction experiments, 293T cells were transfected with 1-2µg of the CMV2Flag vector expressing the Ikaros protein of choice. 24 hours later, cells were fed with fresh media and 48 hours later cells were harvested to prepare nuclear or whole cell extracts. For immunofluorescence studies, NIH-3T3 cells were transfected with 9µg of expression plasmid and 1µg of GH plasmid using ProVera's TransIT-L1 transfection reagent. 36 hours after transfection, cells were harvested for fixation and staining as described below.
Immunoprecipitation and Western Analysis -Whole-cell extracts from 293T cells transfected with the relevant plasmids were prepared as previously described (7) and precleared using Protein-G Agarose beads (Boehringer Mannheim). The pre-cleared extracts were incubated with the antibody of interest or the relevant isotype control on ice for 1hr. 30µl of Protein-G beads were then added to the extract and the extracts were rotated overnight. The beads were collected by centrifugation and washed four times with TS buffer (7). The beads obtained after this procedure were treated with SDS sample buffer, boiled at 95 0 C for 15 minutes and loaded on a SDS-polyacrylamide gel along with 8-10% of the cell extract used for the immunoprecipitation. 
RESULTS

Ikaros' activation function does not rely on a previously identified activation domain -
We have previously shown that ectopic expression of Ikaros and its family members can transactivate reporter genes (5,7). However, the localization of Ikaros in nuclear structures that are in apposition to centromeric heterochromatin and silent genes, coupled with molecular data showing that it can repress transcription, has called into question its function as an activator (12, (20) (21) (22) .
Transcriptional activators typically contain at least one module, termed an activation domain, which is required to enable their interaction with co-activators and the RNA polymerase II complex. Using a yeast one-hybrid assay, a single bipartite activation domain was identified in Ikaros (7). This domain is present at the very Nterminal region of the last exon of Ikaros and is comprised of a putative alpha-helical region followed by a beta sheet, both of which are required for maximal activation in The first class of activation domain mutants we tested consisted of several proline point mutations in the alpha-helical and beta-sheet domains of Ikaros. None of these mutants had any effect on the ability of Ikaros to trans-activate the reporter (data not shown). The helical (-Ah) and beta sheet (-Ab) regions of the activation domain were then respectively deleted in the context of full length Ik1. These deletion mutations also had no effect on transactivation by Ikaros ( Figure 1A ). Finally, an Ikaros mutant with the entire activation domain deleted was tested. Surprisingly, this mutant was fully capable of activation ( Figure 1A ). These findings argue that the previously identified Alternatively, other Ikaros activation domains, if they exist, may not be able to be identified by such assays. c) Ikaros may bind to the backbone of the reporters, which incidentally have several high, medium and low-affinity Ikaros consensus binding sites, and in this manner trans-activate reporter expression from these sites.
Ikaros can function as a non-classical transcriptional activator -
To determine whether Ikaros mediates activation through indirect recruitment, we tested Ikaros' ability to stimulate a diverse series of activators/activation domains as Gal4 fusions. These included Gal4 DBD, Gal4-CTF, Gal4-Ikaros activation domain, Gal4-Sp1 and Gal4-Sp1N (lacking its zinc fingers). The potent repressor, Gal4-Ikaros was also examined. These heterologous proteins were transfected with the reporter 5XGal4 E1B CAT into NIH-3T3 cells in the presence or absence of Ikaros or a dimerization defective Ikaros mutant. Ikaros expression stimulated all of the activation domains tested, albeit to different levels ( Figure 1C ). Even the cryptic activation domain contained in the Gal4 DBD was further enhanced by Ikaros. Only the potent repressor, Gal4-Ik1 (and vector alone) was not activated by Ikaros ( Figure 1C ). Among the activators used, only Sp1 has the potential for direct interaction with Ikaros (J. Koipally, unpublished observations) but this interaction was not required for activation as Sp1N, an
Ikaros/Sp1 interaction mutant, was also stimulated by Ikaros ( Figure 1C binding to DNA and others to re-direct its specificity for DNA. For the design of these mutations, we relied on previous reports on the structure of the zinc finger motif and the amino acids that contact DNA (29, 30) . The Krüppel-type zinc finger motif is comprised of a beta strand and an alpha helix. Amino acids at positions -1, 1, 2, 3 and 6 of the alpha helix make contacts with bases in the major groove of DNA and determine the binding specificity of the protein (29, 30) . Mutations were introduced in the four Ikaros N-terminal zinc fingers at these positions, some of which were expected to disrupt their DNA binding specificity ( Figure 2A) . Two of the second and third zinc finger mutations, f2w and f3m ( Figure 2A ) respectively, had been previously identified in a Jurkat T cell subline and in thymic lymphomas that developed in γ-irradiated mice (31). These mutations had no effect on protein expression ( Figure 2B ).
The DNA binding properties of these Ikaros DBD mutants were examined in vitro using gel shift assays. Wild type and mutant proteins (generated in 293T cells) were One concern when introducing mutations is that they may cause the protein to be misfolded, rather than targeting a specific function. This possibility was examined by testing whether the mutations in the Ikaros DBD influenced the ability of the protein to interact with other factors and engage in the previously characterized Ikaros-chromatin remodeling complexes. All of the Ikaros DBD mutants interacted at wild type levels with
Mi-2β and HDACs, which are Ikaros' major partners in lymphocytes (Fig. 4A ). These mutants were also capable of wild-type interactions with Sin3A and CtBP as well as with other Ikaros isoforms and family members (data not shown). We have previously shown
that Ikaros functions as a strong repressor when tethered to the Gal4 heterologous DNA binding domain (22) . All of the Ikaros DBD mutants were capable of wild type levels of repression in this system, regardless of their ability to bind Ikaros sites (Fig. 4B) . In 
The DNA binding specificity of Ikaros dictates its function as a potentiator -The role of
the Ikaros DBD in potentiation of gene expression was further examined by generating variants with altered DNA binding specificity. The DBD mutants, f2s1 and f2s6, were constructed, based on previously described zinc finger specificity studies, to bind the sequence GGGAG rather than the Ikaros site, GGGAA. This prediction was tested in in vitro DNA binding analysis ( Figure 5A , Ik1, f2s1, f2s6, f2s2 and vector control). Wild type Ikaros protein but not the altered specificity mutants f2s1 and f2s6 interacted with the Ikaros cognate site ( Figure 5A , GGGAA, IKBS2). The altered specificity DBD mutants, f2s1 and f2s6, but not the wild type Ikaros protein, bound to their predicted altered site ( Figure 5A , GGGAG, IKAS1). Another DBD mutant with a mutation in the second zinc finger, f2s2, bound neither the Ikaros nor the altered specificity site ( Figure   5A ). Thus, the DBD mutations f2s1 and f2s6 alter the DNA binding specificity of the protein to GGGAG rather than the GGGAA Ikaros consensus.
We next tested whether the f2s1 and f2s6 altered specificity mutants could transactivate from their recognition sites introduced upstream of the tkCAT reporter. NIH-3T3 cells were co-transfected with the altered specificity reporter, 4XIKAS1tkCAT and the altered specificity mutants or the wild type Ikaros protein. Surprisingly, the altered specificity mutants f2s1 and f2s6, like f2s2, did not trans-activate the reporter even though they were able to bind their altered specificity binding site IKAS1 ( Figure 5A ). In a separate experiment, another Ikaros altered specificity mutant, f3s1, which can bind to the GAGAA sequence, also failed to trans-activate from its cognate site introduced upstream of the tkCAT reporter (data not shown). In contrast, the wild type Ikaros protein (Ik1) trans-activated these reporters.
Taken together, these data argue not only that DNA binding is important for
Ikaros' ability to stimulate transcription, but also that the nature of the Ikaros binding domain and the context of its site may ultimately dictate its function in transcriptional regulation. These findings also provide an important distinction between the activation and repression properties of Ikaros; although they both rely on DNA binding, only the latter can be rescued by a heterologous DNA binding domain. that surround the densely staining heterochromatin (Fig. 6A) . Mutations in the DBD which do not alter its specificity or affinity for DNA (f1s1, Rbm and f4s1) did not interfere with the localization of the protein in the heterochromatin-associated toroidal structures ( Fig. 6A and data not shown). Mutations that alter but do not completely ablate DNA binding reduced the amount of protein in these structures (Fig. 6A, f3m ). In contrast, mutations that ablate DNA binding (f2s1, f2s2 and f2s6) did not allow localization in these toroids; instead the mutant proteins were diffusely distributed throughout the nucleus and in some instances were also found in the cytoplasm (Fig. 6A and data not shown). Thus, all Ikaros DBD mutants that bind DNA and activate transcription localize to heterochromatin-associated nuclear structures in actively cycling NIH-3T3 cells. In contrast, the mutants that do not bind wild type Ikaros sites and do not activate transcription are non-heterochromatic in their localization. These data identify a striking correlation between Ikaros' ability to activate transcription and its localization to heterochromatin-associated environments.
Ikaros' ability to potentiate gene expression correlates with its targeting to PC-HC -
We have previously shown that in lymphocytes the majority of Ikaros protein and its family members associate with the ATPase Mi-2β in a lymphoid-specific version of the NuRD complex (21) . Upon lymphocyte activation, there is a dramatic re-distribution of Ikaros and Mi-2β to heterochromatin-associated toroids; however, in Ikaros null lymphocytes Mi-2β is diffusely distributed, suggesting that Ikaros is responsible for its heterochromatic localization (21) . In fibroblasts, which lack Ikaros, Mi-2β is also diffusely distributed throughout the nucleus (Fig. 6B) . However, when Ikaros is ectopically expressed in these cells, both Ikaros and Mi-2β proteins localize to pericentric heterochromatin-associated toroids. These data provide unequivocal evidence that Ikaros targets Mi-2β to centromeric sites ( Fig. 6B and data not shown).
Targeting of Mi-2β by Ikaros to PC-HC may be pertinent to the mechanism that underlies Ikaros' potentiation function.
DISCUSSION
It is well established that Ikaros plays a critical role at many distinct steps of the hemo- Further insight into the question of binding site context is provided by the ability of Ikaros proteins in cycling cells to redistribute into toroidal structures surrounding pericentric heterochromatin (12, 20) . This targeting event requires an intact Ikaros DBD and is presumed to occur through interactions of Ikaros with its cognate binding sites in γ↑ satellite repeats of peri-centromeric heterochromatin (27) . In support of this hypothesis, no sites corresponding to the cognate sites of the altered specificity mutants reported here were present in γ-satellite DNA. Unexpectedly, the ability of Ikaros to localize to heterochromatin correlates with its ability to potentiate gene expression. Ikaros DBD mutants that were unable to localize into heterochromatin-associated structures were unable to activate gene expression. On the other hand, every activation competent DBD mutant could localize to heterochromatin. The current data suggests that Ikaros may support transcription when localized to heterochromatin since the majority of Ikaros proteins in the cell line assayed are found in this compartment and because Ikaros enhances activation in these cells.
Based on these findings, we propose two non-mutually exclusive models to 
